Join
Live feed
·
INSIDERFilingvia Quantisnow
Maze Therapeutics Inc. logo

President, R&D & CMO Bernstein Harold sold $254,502 worth of shares (9,705 units at $26.22) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
MAZE· Maze Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MAZE (Maze Therapeutics Inc.) and more on Quantisnow.